Neurological Sciences

, Volume 39, Issue 1, pp 141–143 | Cite as

Rasagiline for dysexecutive symptoms during wearing-off in Parkinson’s disease: a pilot study

  • Domiziana Rinaldi
  • Francesca Assogna
  • Michela Sforza
  • Stefania Tagliente
  • Francesco E. PontieriEmail author
Brief Communication


Wearing-off refers to the predictable worsening of motor and sometimes non-motor symptoms of Parkinson’s disease occurring at the end of levodopa dose that improves with the next drug dose. Here, we investigated the efficacy of rasagiline on executive functions at the end of levodopa dose in patients displaying symptoms of wearing-off. Rasagiline was well-tolerated and produced a significant improvement at the Frontal Assessment Battery, together with improvement of motor symptoms at the end of levodopa dose. These results suggest that treatment of motor symptoms of wearing-off with rasagiline may be accompanied by improvement of executive functions, and further support the need for optimizing dopamine replacement therapy in fluctuating Parkinson’s disease patients.


Cognition Frontal Assessment Battery Parkinson’s disease Rasagiline Wearing-off 


Funding source

Supported by a research grant from Lundbeck to FEP

Compliance with ethical standards

This pilot study was approved by the local Ethical Committee, and each subject signed informed consent before enrollment.

Conflict of interest

FEP received honoraria for speaking at symposia from Abbvie and Zambon. The other authors have no conflict of interest to declare.


  1. 1.
    Pahwa R, Lyons KE (2009) Levodopa-related wearing-off in Parkinson’s disease: identification and management. Curr Med Res Opin 25:841–849CrossRefPubMedGoogle Scholar
  2. 2.
    Stocchi F, Fossati C, Torti M (2015) Rasagiline for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother 16:2231–2241CrossRefPubMedGoogle Scholar
  3. 3.
    Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, Gunal DI, Yener GC, Cakmur R, Sahin HA, Emre M (2011) The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 26:1851–1858CrossRefPubMedGoogle Scholar
  4. 4.
    Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X, COMPASS-I Study Investigators (2008) The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 14:205–212CrossRefPubMedGoogle Scholar
  5. 5.
    Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324CrossRefPubMedGoogle Scholar
  6. 6.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Publishing, WashingtonGoogle Scholar
  7. 7.
    Marconi R, Antonini A, Barone P et al (2012) Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Neurol Sci 33:585–593CrossRefPubMedGoogle Scholar
  8. 8.
    Spalletta G, Robinson RG, Cravello L, Pontieri FE, Pierantozzi M, Stefani A, Long JD, Caltagirone C, Assogna F (2014) The early course of affective and cognitive symptoms in de novo patients with Parkinson’s disease. J Neurol 261:1126–1132CrossRefPubMedGoogle Scholar
  9. 9.
    Macdonald PA, Macdonald AA, Seergobin KN, Tamjeedi R, Ganjavi H, Provost JS, Monchi O (2011) The effects of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson’s disease: support from functional MRI. Brain 134:1447–1463CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l. 2017

Authors and Affiliations

  1. 1.Dipartimento di Neuroscience, Salute Mentale e Organi di Senso“Sapienza” Università di RomaRomeItaly
  2. 2.Museo Storico della Fisica e Centro Studi e Ricerche “Enrico Fermi”RomeItaly
  3. 3.IRCCS “Fondazione Santa Lucia”RomeItaly

Personalised recommendations